Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy

Molecular Cancer Therapeutics - Tập 8 Số 5 - Trang 1292-1304 - 2009
David M. Su1,2,3,4,5, Qiuyang Zhang1,2,3,4,5, Xuexi Wang1,2,3,5, Ping He1,2,3,4,5, Yuelin J. Zhu1,2,3,4,5, Jianxiong Zhao1,2,3,4,5, Owen M. Rennert1,2,3,4,5, Yan Su1,2,3,4,5
11Department of Biochemistry and Molecular Biology and the Catherine Birch McCormick Genomics Center, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia; 2The Institution of Chinese-Western Integrative Medicine, Lanzhou University School of Medical Science, Lanzhou, Gansu, China; 3Laboratory of Cellular Hemostasis, Division of Hematology, Center for Biological Evaluation and Research, Food and Drug Administration; 4Laboratory of Clinical Genomics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland; and 5Advanced Biomedical Computing Center, National Cancer Institute-Frederick/Science Applications International Corporation-Frederick, Inc., Frederick, Maryland
2Advanced Biomedical Computing Center, National Cancer Institute-Frederick/Science Applications International Corporation-Frederick, Inc., Frederick, Maryland
3Laboratory of Cellular Hemostasis, Division of Hematology, Center for Biological Evaluation and Research, Food and Drug Administration
4Laboratory of Clinical Genomics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland
5The Institution of Chinese-Western Integrative Medicine, Lanzhou University School of Medical Science, Lanzhou, Gansu, China

Tóm tắt

Abstract Human malignant melanoma has poor prognosis because of resistance to apoptosis and therapy. We describe identification of the expression profile of 1,037 mitochondria-focused genes and 84 survival-apoptosis genes in 21 malignant melanoma cell lines and 3 normal melanocyte controls using recently developed hMitChip3 cDNA microarrays. Unsupervised hierarchical clustering analysis of 1,037 informative genes, and 84 survival-apoptosis genes, classified these malignant melanoma cell lines into type A (n = 12) and type B (n = 9). Three hundred fifty-five of 1,037 (34.2%) genes displayed significant (P ≤ 0.030; false discovery rate ≤ 3.68%) differences (±≥2.0-fold) in average expression, with 197 genes higher and 158 genes lower in type A than in type B. Of 84 genes with known survival-apoptosis functions, 38 (45.2%) displayed the significant (P < 0.001; false discovery rate < 0.15%) difference. Antiapoptotic (BCL2, BCL2A1, PPARD, and RAF1), antioxidant (MT3, PRDX5, PRDX3, GPX4, GLRX2, and GSR), and proapoptotic (BAD, BNIP1, APAF1, BNIP3L, CASP7, CYCS, CASP1, and VDAC1) genes expressed at higher levels in type A than in type B, whereas the different set of antiapoptotic (PSEN1, PPP2CA, API5, PPP2R1B, PPP2R1A, and FIS1), antioxidant (HSPD1, GSS, SOD1, ATOX1, and CAT), and proapoptotic (ENDOG, BAK1, CASP2, CASP4, PDCD5, HTRA2, SEPT4, TNFSF10, and PRODH) genes expressed at lower levels in type A than in type B. Microarray data were validated by quantitative reverse transcription-PCR. These results showed the presence of two types of malignant melanoma, each with a specific set of dysregulated survival-apoptosis genes, which may prove useful for development of new molecular targets for therapeutic intervention and novel diagnostic biomarkers for treatment and prognosis of malignant melanoma.[Mol Cancer Ther 2009;8(5):OF1–13]

Từ khóa


Tài liệu tham khảo

American Cancer Society, 2008, Cancer facts and figures 2008, 1

Gray-Schopfer, 2007, Melanoma biology and new targeted therapy, Nature, 445, 851, 10.1038/nature05661

MacKie, 2007, Melanoma incidence and mortality in Scotland 1979-2003, Br J Cancer, 96, 1772, 10.1038/sj.bjc.6603801

Garbe, 2001, Epidemiology of cutaneous melanoma in Germany and worldwide, Skin Pharmacol Appl Skin Physiol, 14, 280, 10.1159/000056358

Lens, 2004, Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma, Br J Dermatol, 150, 179, 10.1111/j.1365-2133.2004.05708.x

Eigentler, 2003, Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials, Lancet Oncol, 4, 748, 10.1016/S1470-2045(03)01280-4

Schadendorf, 2006, Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG, Ann Oncol, 17, 563, 10.1093/annonc/mdj138

Tuettenberg, 2007, Dendritic cell-based immunotherapy of malignant melanoma: success and limitations, J Dtsch Dermatol Ges, 5, 190, 10.1111/j.1610-0387.2007.06179.x

Middleton, 2000, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma, J Clin Oncol, 18, 158, 10.1200/JCO.2000.18.1.158

Bedikian, 2006, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group, J Clin Oncol, 24, 4738, 10.1200/JCO.2006.06.0483

Meier, 1998, Molecular events in melanoma development and progression, Front Biosci, 3, D1005, 10.2741/A341

Kim, 2006, The role of apoptosis in cancer cell survival and therapeutic outcome, Cancer Biol Ther, 5, 1429, 10.4161/cbt.5.11.3456

Zhang, 2007, Differences in apoptosis and cell cycle distribution between human melanoma cell lines UACC903 and UACC903(+6), before and after UV irradiation, Int J Biol Sci, 3, 342, 10.7150/ijbs.3.342

Zhang, 2008, Molecular mechanism underlying differential apoptosis between human melanoma cell lines UACC903 and UACC903(+6) revealed by mitochondria-focused cDNA microarrays, Apoptosis, 13, 993, 10.1007/s10495-008-0231-8

Bai, 2007, Third-generation human mitochondria-focused cDNA microarray and its bioinformatic tools for analysis of gene expression, Biotechniques, 42, 365, 10.2144/000112388

Su, 1996, Reversion of monochromosome-mediated suppression of tumorigenicity in malignant melanoma by retroviral transduction, Cancer Res, 56, 3186

Trent, 1990, Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6, Science, 247, 568, 10.1126/science.2300817

Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185

Eisen, 1998, Cluster analysis and display of genome-wide expression patterns, Proc Natl Acad Sci U S A, 95, 14863, 10.1073/pnas.95.25.14863

Manoli, 2005, Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells, FASEB J, 19, 1359, 10.1096/fj.04-3660fje

Holland, 1991, Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase, Proc Natl Acad Sci U S A, 88, 7276, 10.1073/pnas.88.16.7276

Benjamini, 1995, Controlling the false discovery rate—a practical and powerful approach to multiple testing, J R Stat Soc Ser B Methodol, 57, 289

Seftor, 2002, Molecular determinants of human uveal melanoma invasion and metastasis, Clin Exp Metastasis, 19, 233, 10.1023/A:1015591624171

Lee, 2000, Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations, Proc Natl Acad Sci U S A, 97, 9834, 10.1073/pnas.97.18.9834

Soengas, 2003, Apoptosis and melanoma chemoresistance, Oncogene, 22, 3138, 10.1038/sj.onc.1206454

Eberle, 2007, Overcoming apoptosis deficiency of melanoma—hope for new therapeutic approaches, Drug Resist Updat, 10, 218, 10.1016/j.drup.2007.09.001

Eberle, 2007, Apoptosis pathways as promising targets for skin cancer therapy, Br J Dermatol, 156 Suppl 3, 18, 10.1111/j.1365-2133.2007.07855.x

Lin, 2008, Modeling genomic diversity and tumor dependency in malignant melanoma, Cancer Res, 68, 664, 10.1158/0008-5472.CAN-07-2615

Lorigan, 2008, Systemic therapy for metastatic malignant melanoma—from deeply disappointing to bright future?, Exp Dermatol, 17, 383, 10.1111/j.1600-0625.2007.00673.x

Ikoma, 2005, S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/γCnull (NOG) mouse model, Oncol Rep, 14, 633

Welch, 1991, Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line, Int J Cancer, 47, 227, 10.1002/ijc.2910470211

Gouon, 1996, Up-regulated expression of the β3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice, Int J Cancer, 68, 650, 10.1002/(SICI)1097-0215(19961127)68:5<650::AID-IJC16>3.0.CO;2-5

Thies, 2007, Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice, Br J Cancer, 96, 609, 10.1038/sj.bjc.6603594

Luca, 1995, Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis, Oncogene, 11, 1399

Su, 2000, Identification of tumor-suppressor genes using human melanoma cell lines UACC903, UACC903(+6), and SRS3 by comparison of expression profiles, Mol Carcinog, 28, 119, 10.1002/1098-2744(200006)28:2<119::AID-MC8>3.0.CO;2-N

Thông tin
Thông tin xuất bản

Molecular Cancer Therapeutics

Tập 8 Số 5

1292-1304

Thông tin tác giả